Drug repurposing to target proteostasis and prevent neurodegeneration: accelerating translational efforts

Gabriela Mercado^{1

2

3}, Claudio Hetz^{1

2

3

4

5}

Affiliations

¹ Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile.
² Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
³ Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
⁴ Buck Institute for Research on Aging, Novato, CA, 94945, USA.
⁵ Department of Immunology and Infectious diseases, Harvard School of Public Health, 02115 Boston MA, USA.

Comment

Gabriela Mercado et al. Brain. 2017.

. 2017 Jun 1;140(6):1544-1547.

doi: 10.1093/brain/awx107.

Gabriela Mercado^{1

2

3}, Claudio Hetz^{1

2

3

4

5}

¹ Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile.
² Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
³ Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
⁴ Buck Institute for Research on Aging, Novato, CA, 94945, USA.
⁵ Department of Immunology and Infectious diseases, Harvard School of Public Health, 02115 Boston MA, USA.

No abstract available

Comment on

Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice.
Halliday M, Radford H, Zents KAM, Molloy C, Moreno JA, Verity NC, Smith E, Ortori CA, Barrett DA, Bushell M, Mallucci GR. Halliday M, et al. Brain. 2017 Jun 1;140(6):1768-1783. doi: 10.1093/brain/awx074. Brain. 2017. PMID: 28430857 Free PMC article.